Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance

Chemotherapy and immunotherapy have markedly improved the management of several malignancies. However, not all cancer patients respond primarily to such therapies, and others can become resistant during treatment. Thus, identification of the factors/mechanisms underlying cancer resistance to such tr...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-02, Vol.15 (3), p.971
Main Authors: Monteleone, Giovanni, Franzè, Eleonora, Maresca, Claudia, Colella, Marco, Pacifico, Teresa, Stolfi, Carmine
Format: Article
Language:English
Subjects:
Apoptosis
Biomarkers
Breast cancer
Cancer
Cancer therapies
Care and treatment
Cell differentiation
Cells
Chemotherapy
Colorectal cancer
Cytokines
Cytotoxicity
Drug resistance
Drug targeting
Drugs
FDA approval
Health aspects
Hepatitis
Immunoregulation
Immunosuppression
Immunosuppressive agents
Immunotherapy
Interleukins
Kinases
Leukemia
Ligands
Liver cancer
Lung cancer
Lymphocyte receptors
Lymphocytes T
Macrophages
Malignancy
Mammography
Metastasis
Methods
Monoclonal antibodies
Mutation
Oncology, Experimental
Proteins
Review
Suppressor cells
Tumor microenvironment
Tumors
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chemotherapy and immunotherapy have markedly improved the management of several malignancies. However, not all cancer patients respond primarily to such therapies, and others can become resistant during treatment. Thus, identification of the factors/mechanisms underlying cancer resistance to such treatments could help develop novel effective therapeutic compounds. Tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs) are major components of the suppressive tumor microenvironment and are critical drivers of immunosuppression, creating a tumor-promoting and drug-resistant niche. In this regard, therapeutic strategies to tackle immunosuppressive cells are an interesting option to increase anti-tumor immune responses and overcome the occurrence of drug resistance. Accumulating evidence indicates that interleukin-34 (IL-34), a cytokine produced by cancer cells, and/or TAMs act as a linker between induction of a tumor-associated immunosuppressive microenvironment and drug resistance. In this article, we review the current data supporting the role of IL-34 in the differentiation/function of immune suppressive cells and, hence, in the mechanisms leading to therapeutic resistance in various cancers.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15030971